Ask AI
Bill118th CongressFiled Nov 3, 2023Health
H.R. 6227

Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023

Bill journey · stage 2 of 5

Under committee review

Filed
Comm.
Floor
Both
Law

What it doesSummary introduced in house (Nov 3, 2023)

Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023

This bill expands the priority-review voucher program for tropical diseases to include coccidioidomycosis (also known as Valley fever). A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.

What just happenedNov 10, 2023

Referred to the Subcommittee on Health.

Who’s behind it

Rep. Schweikert, David [R-AZ-1](R-AZ)Sponsor
35 cosponsors14 D21 R
Read on Congress.gov
35cosponsors1committees4actions3related bills4subjects
  1. Nov 10, 2023Committee

    Referred to the Subcommittee on Health.

    Health Subcommittee
  2. Nov 3, 2023IntroReferralH11100

    Referred to the House Committee on Energy and Commerce.

    Energy and Commerce Committee
  3. Nov 3, 2023IntroReferralIntro-H

    Introduced in House

  4. Nov 3, 2023IntroReferral1000

    Introduced in House

Adding Coccidioidomycosis to the FDA Priority Review Voucher Program Act of 2023 — Informed